drug

Sulforaphane Nutraceutical

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Sheppard Pratt Health System
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Sulforaphane to Reduce Symptoms of Schizophrenia
NCT02810964Phase 2Completed

KOLs & investigators

1
Faith B Dickerson, PhD, MPHKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Sheppard Pratt Health System
company
trial
Sulforaphane to Reduce Symptoms of Schizophrenia
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Faith B Dickerson, PhD, MPH
KOL score 5
person